<?xml version="1.0" encoding="UTF-8"?>
<resource xmlns="http://datacite.org/schema/kernel-4" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://datacite.org/schema/kernel-4 http://schema.datacite.org/meta/kernel-4.1/metadata.xsd">
  <identifier identifierType="DOI">10.18453/rosdok_id00001240</identifier>
  <creators>
    <creator>
      <creatorName nameType="Personal">Casalegno Garduño, Rosaely</creatorName>
      <givenName>Rosaely</givenName>
      <familyName>Casalegno Garduño</familyName>
      <nameIdentifier nameIdentifierScheme="GND" schemeURI="http://d-nb.info/gnd/">http://d-nb.info/gnd/1025918991</nameIdentifier>
    </creator>
  </creators>
  <titles>
    <title>Expression of and immune responses to leukemia antigens in patients with hematological malignancies</title>
  </titles>
  <publisher>Universität Rostock</publisher>
  <publicationYear>2013</publicationYear>
  <resourceType resourceTypeGeneral="Text" />
  <subjects>
    <subject xml:lang="en" schemeURI="http://dewey.info/" subjectScheme="dewey">610 Medical sciences Medicine</subject>
    <subject xml:lang="en" schemeURI="http://dewey.info/" subjectScheme="dewey">570 Life science</subject>
  </subjects>
  <dates>
    <date dateType="Created">2013</date>
  </dates>
  <language>en</language>
  <alternateIdentifiers>
    <alternateIdentifier alternateIdentifierType="PURL">http://purl.uni-rostock.de/rosdok/id00001240</alternateIdentifier>
    <alternateIdentifier alternateIdentifierType="URN">urn:nbn:de:gbv:28-diss2013-0153-1</alternateIdentifier>
  </alternateIdentifiers>
  <descriptions>
    <description descriptionType="Abstract">Leukemia cells are characterized by differentially expressed leukemia-associated antigens (LAAs). We wondered whether the expression of the LAAs WT1 and RHAMM as well as the T cellular immune response to these LAAs correlated with the clinical outcome of patients suffering from leukemia. We investigated the expression of WT1 and RHAMM at RNA level using qPCR before and after treatment. We concluded that WT1 is a suitable marker for MRD after allogeneic SCT and that a WT1-specific T cell response might contribute to the maintenance of CR.</description>
  </descriptions>
</resource>
